238 related articles for article (PubMed ID: 28328012)
1. Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges.
Li Z; Xu X; Huang W; Qian H
Med Res Rev; 2018 Mar; 38(2):381-425. PubMed ID: 28328012
[TBL] [Abstract][Full Text] [Related]
2. Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus.
Rani L; Grewal AS; Sharma N; Singh S
Mini Rev Med Chem; 2021; 21(4):426-470. PubMed ID: 33100202
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances in Development of GPR40 Modulators (FFA1/FFAR1): An Emerging Target for Type 2 Diabetes.
Sharma N; Bhagat S; Chundawat TS
Mini Rev Med Chem; 2017; 17(11):947-958. PubMed ID: 28117025
[TBL] [Abstract][Full Text] [Related]
4. Current status of GPR40/FFAR1 modulators in medicinal chemistry (2016-2019): a patent review.
Li Z; Zhou Z; Zhang L
Expert Opin Ther Pat; 2020 Jan; 30(1):27-38. PubMed ID: 31771391
[No Abstract] [Full Text] [Related]
5. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARĪ³/FFAR1 dual agonists.
Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
[TBL] [Abstract][Full Text] [Related]
6. Free fatty acid receptor 1 as a novel therapeutic target for type 2 diabetes mellitus-current status.
Eleazu C; Charles A; Eleazu K; Achi N
Chem Biol Interact; 2018 Jun; 289():32-39. PubMed ID: 29704509
[TBL] [Abstract][Full Text] [Related]
7. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
Chen C; Li H; Long YQ
Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762
[TBL] [Abstract][Full Text] [Related]
8. Synthetic GPR40/FFAR1 agonists: An exhaustive survey on the most recent chemical classes and their structure-activity relationships.
Paul A; Nahar S; Nahata P; Sarkar A; Maji A; Samanta A; Karmakar S; Maity TK
Eur J Med Chem; 2024 Jan; 264():115990. PubMed ID: 38039791
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and structure-activity relationship studies of GPR40 agonists containing amide linker.
Chen T; Ning M; Ye Y; Wang K; Leng Y; Shen J
Eur J Med Chem; 2018 May; 152():175-194. PubMed ID: 29705709
[TBL] [Abstract][Full Text] [Related]
10. FFAR1/GPR40: One target, different binding sites, many agonists, no drugs, but a continuous and unprofitable tug-of-war between ligand lipophilicity, activity, and toxicity.
Governa P; Caroleo MC; Carullo G; Aiello F; Cione E; Manetti F
Bioorg Med Chem Lett; 2021 Jun; 41():127969. PubMed ID: 33771587
[TBL] [Abstract][Full Text] [Related]
11. An updated patent review of GPR40/ FFAR1 modulators (2020 - present).
Ren Q; Fan Y; Yang L; Shan M; Shi W; Qian H
Expert Opin Ther Pat; 2023; 33(9):565-577. PubMed ID: 37947382
[TBL] [Abstract][Full Text] [Related]
12. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
Hamdouchi C; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Eessalu TE; Ficorilli JV; Marcelo MC; Otto KA; Wilbur KL; Lineswala JP; Piper JL; Coffey DS; Sweetana SA; Haas JV; Brooks DA; Pratt EJ; Belin RM; Deeg MA; Ma X; Cannady EA; Johnson JT; Yumibe NP; Chen Q; Maiti P; Montrose-Rafizadeh C; Chen Y; Reifel Miller A
J Med Chem; 2016 Dec; 59(24):10891-10916. PubMed ID: 27749056
[TBL] [Abstract][Full Text] [Related]
13. Free fatty acid receptor 1: a ray of hope in the therapy of type 2 diabetes mellitus.
Arora A; Behl T; Sehgal A; Singh S; Sharma N; Chigurupati S; Kaur R; Bhatia S; Al-Harrasi A; Vargas-De-La-Cruz C; Bungau S
Inflammopharmacology; 2021 Dec; 29(6):1625-1639. PubMed ID: 34669065
[TBL] [Abstract][Full Text] [Related]
14. Free Fatty Acid Receptors (FFARs): Emerging Therapeutic Targets for the Management of Diabetes Mellitus.
Loona DPS; Das B; Kaur R; Kumar R; Yadav AK
Curr Med Chem; 2023; 30(30):3404-3440. PubMed ID: 36173072
[TBL] [Abstract][Full Text] [Related]
15. GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.
Mancini AD; Poitout V
Diabetes Obes Metab; 2015 Jul; 17(7):622-9. PubMed ID: 25604916
[TBL] [Abstract][Full Text] [Related]
16. A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1.
Yabuki C; Komatsu H; Tsujihata Y; Maeda R; Ito R; Matsuda-Nagasumi K; Sakuma K; Miyawaki K; Kikuchi N; Takeuchi K; Habata Y; Mori M
PLoS One; 2013; 8(10):e76280. PubMed ID: 24130766
[TBL] [Abstract][Full Text] [Related]
17. Physiology and therapeutics of the free fatty acid receptor GPR40.
Huang H; Dai MH; Tao YX
Prog Mol Biol Transl Sci; 2014; 121():67-94. PubMed ID: 24373235
[TBL] [Abstract][Full Text] [Related]
18. Modulating GPR40: therapeutic promise and potential in diabetes.
Poitout V; Lin DC
Drug Discov Today; 2013 Dec; 18(23-24):1301-8. PubMed ID: 24051395
[TBL] [Abstract][Full Text] [Related]
19. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.
Bharate SB; Nemmani KV; Vishwakarma RA
Expert Opin Ther Pat; 2009 Feb; 19(2):237-64. PubMed ID: 19441920
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel GPR40 agonists.
Jiang XW; Jiang BE; Liu H; Liu ZT; Hu LL; Liu M; Lu W; Zhang HK
Eur J Med Chem; 2018 Oct; 158():123-133. PubMed ID: 30212763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
